A randomized, phase II, double-blinded study of the efficacy of oleogel-S10 (AP101) gel for the treatment of grade 2/3 radiation dermatitis in breast cancer patients. (ASCO 2026) - Apr 21, 2026 - Abstract #e24199; P2 | "Patients were randomized 1:1 to Oleogel-S10 or placebo and instructed to apply standard-of-care triamcinolone 0.1% cream daily with study gel nightly for three weeks. Although Oleogel-S10 did not improve the primary endpoint of wound surface area as calculated by a novel 3D imaging tool compared with standard-of-care triamcinolone, treatment was associated with a trend toward improvement in skin pain and hyperpigmentation. These findings may represent early signals of therapeutic activity in ARD, particularly for patient-centered outcomes. Interpretation is limited by early study closure related to COVID-19–associated recruitment challenges and small sample size."
Clinical • P2 data • Breast Cancer • Dermatitis • Dermatology • Immunology • Infectious Disease • Oncology • Pruritus • Skin Cancer • Solid Tumor
|
|
Tara Maier; Amy Xu; Stephen Dusza; Simon Powell; Andrew Barsky; Michael Bernstein; John Cuaron; Beryl McCormick; Marsha Reyngold; Dhwani Parikh; Alina Markova
|